Advertisement

Cystic Fibrosis Foundation Practice Guidelines for the Management of Infants with Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome during the First Two Years of Life and Beyond

      Through early detection, newborn screening (NBS)
      • Comeau A.M.
      • Parad R.
      • Gerstle R.
      • O'Sullivan B.P.
      • Dorkin H.L.
      • Dovey M.
      • et al.
      Challenges in implementing a successful newborn cystic fibrosis screening program.
      for cystic fibrosis (CF) offers the opportunity for early intervention and improved outcomes. NBS programs screen for hypertrypsinogenemia, and most also identify mutations in the CF transmembrane conductance regulator (CFTR) gene. Individuals identified by NBS are diagnosed with CF if they have an elevated sweat chloride level or if they have inherited 2 disease-causing mutations in the CFTR gene. Mutations in the CFTR gene can cause CF, but not all CFTR mutations are disease-causing. The term CFTR-related metabolic syndrome (CRMS) is proposed to describe infants identified by hypertrypsinogenemia on NBS who have sweat chloride values <60 mmol/L and up to 2 CFTR mutations, at least 1 of which is not clearly categorized as a “CF-causing mutation,” thus they do not meet CF Foundation guidelines for the diagnosis of CF. With what is now near-universal CF NBS in the United States, an increasing number of infants with CRMS are being identified. Given our inadequate knowledge of the natural history of CRMS, standards for diagnosis, monitoring, and treatment are absent. This document aims to help guide the monitoring and care of individuals with CRMS while our knowledge base on appropriate management evolves.
      CF (Cystic fibrosis), CFTR (Cystic fibrosis transmembrane conductance regulator), CRMS (CFTR-related metabolic syndrome), NBS (Newborn screening), PCP (Primary care provider), PS (Pancreatic sufficient), RSV (Respiratory syncytial virus), TG (Thymidine-guanine)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pediatrics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Comeau A.M.
        • Parad R.
        • Gerstle R.
        • O'Sullivan B.P.
        • Dorkin H.L.
        • Dovey M.
        • et al.
        Challenges in implementing a successful newborn cystic fibrosis screening program.
        J Pediatr. 2005; 147: S89-S93
        • Borowitz D.
        • Rosenfeld M.
        • Davis S.
        • Sabadosa K.
        • Spear S.
        • Michel S.
        • et al.
        Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.
        J Pediatr. 2009; 155: S96-S116
        • Farrell P.M.
        • Rosenstein B.J.
        • White T.B.
        • Accurso F.J.
        • Castellani C.
        • Cutting G.R.
        • et al.
        Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.
        J Pediatr. 2008; 153: S4-S14
        • Castellani C.
        • Cuppens H.
        • Macek Jr., M.
        • Cassiman J.J.
        • Kerem E.
        • Durie P.
        • et al.
        Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.
        J Cyst Fibros. 2008; 7: 179-196
      1. Linstone HA, Turoff M. http://is.njit.edu/pubs/delphibook. Accessed 10/19/2009.

        • Scotet V.
        • Audrezet M.P.
        • Roussey M.
        • Rault G.
        • Dirou-Prigent A.
        • Journel H.
        • et al.
        Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?.
        Pediatrics. 2006; 118: e1523-e1529
        • Massie R.J.
        • Poplawski N.
        • Wilcken B.
        • Goldblatt J.
        • Byrnes C.
        • Robertson C.
        Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C.
        Eur Respir J. 2001; 17: 1195-1200
        • Peckham D.
        • Conway S.P.
        • Morton A.
        • Jones A.
        • Webb K.
        Delayed diagnosis of cystic fibrosis associated with R117H on a background of 7T polythymidine tract at intron 8.
        J Cyst Fibros. 2006; 5: 63-65
        • O'Sullivan B.P.
        • Zwerdling R.G.
        • Dorkin H.L.
        • Comeau A.M.
        • Parad R.
        Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype.
        Pediatrics. 2006; 118: 1260-1265
        • Roussey M.
        • Le Bihannic A.
        • Scotet V.
        • Audrezet M.P.
        • Blayau M.
        • Dagorne M.
        • et al.
        Neonatal screening of cystic fibrosis: diagnostic problems with CFTR mild mutations.
        J Inherit Metab Dis. 2007; 30: 613
        • Mussaffi H.
        • Prais D.
        • Mei-Zahav M.
        • Blau H.
        Cystic fibrosis mutations with widely variable phenotype: the D1152H example.
        Pediatr Pulmonol. 2006; 41: 250-254
        • Durno C.
        • Corey M.
        • Zielenski J.
        • Tullis E.
        • Tsui L.C.
        • Durie P.
        Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis.
        Gastroenterology. 2002; 123: 1857-1864
        • Noone P.G.
        • Pue C.A.
        • Zhou Z.
        • Friedman K.J.
        • Wakeling E.L.
        • Ganeshananthan M.
        • et al.
        Lung disease associated with the IVS8 5T allele of the CFTR gene.
        Am J Respir Crit Care Med. 2000; 162: 1919-1924
        • Groman J.D.
        • Hefferon T.W.
        • Casals T.
        • Bassas L.
        • Estivill X.
        • Des Georges M.
        • et al.
        Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign.
        Am J Hum Genet. 2004; 74: 176-179
        • Fajac I.
        • Viel M.
        • Sublemontier S.
        • Hubert D.
        • Bienvenu T.
        Could a defective epithelial sodium channel lead to bronchiectasis.
        Respir Res. 2008; 9: 46
        • Sims E.J.
        • Clark A.
        • McCormick J.
        • Mehta G.
        • Connett G.
        • Mehta A.
        Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy.
        Pediatrics. 2007; 119: 19-28
        • Farrell P.M.
        The meaning of “early” diagnosis in a new era of cystic fibrosis care.
        Pediatrics. 2007; 119: 156-157
        • Saiman L.
        • Siegel J.
        Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.
        Infect Control Hosp Epidemiol. 2003; 24: S6-52
        • Mayell S.J.
        • Munck A.
        • Craig J.V.
        • Sermet I.
        • Brownlee K.G.
        • Schwarz M.J.
        • et al.
        A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis.
        J Cyst Fibros. 2009; 8: 71-78
        • Lording A.
        • McGaw J.
        • Dalton A.
        • Beal G.
        • Everard M.
        • Taylor C.J.
        Pulmonary infection in mild variant cystic fibrosis: implications for care.
        J Cyst Fibros. 2006; 5: 101-104
        • O'Sullivan B.P.C.E.
        • Carlson D.
        • Parad R.
        • Comeau A.M.
        Oropharyngeal flora in non-CF infants.
        Pediatr Pulmonol. 2009; 44: 497-502
        • Van Ewijk B.E.
        • Wolfs T.F.
        • Aerts P.C.
        • Van Kessel K.P.
        • Fleer A.
        • Kimpen J.L.
        • et al.
        RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells.
        Pediatr Res. 2007; 61: 398-403
        • Feldmann D.
        • Couderc R.
        • Audrezet M.P.
        • Ferec C.
        • Bienvenu T.
        • Desgeorges M.
        • et al.
        CFTR genotypes in patients with normal or borderline sweat chloride levels.
        Hum Mutat. 2003; 22: 340
        • Kopelman H.
        • Corey M.
        • Gaskin K.
        • Durie P.
        • Weizman Z.
        • Forstner G.
        Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas.
        Gastroenterology. 1988; 95: 349-355
        • Nousia-Arvanitakis S.
        • Karagiozoglou-Lamboudes T.
        • Aggouridaki C.
        • Malaka-Lambrellis E.
        • Galli-Tsinopoulou A.
        • Xefteri M.
        Influence of jejunal morphology changes on exocrine pancreatic function in celiac disease.
        J Pediatr Gastroenterol Nutr. 1999; 29: 81-85
        • Walkowiak J.
        • Herzig K.H.
        Fecal elastase-1 is decreased in villous atrophy regardless of the underlying disease.
        Eur J Clin Invest. 2001; 31: 425-430
        • Chillon M.
        • Casals T.
        • Mercier B.
        • Bassas L.
        • Lissens W.
        • Silber S.
        • et al.
        Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens.
        N Engl J Med. 1995; 332: 1475-1480
        • Mak V.
        • Zielenski J.
        • Tsui L.C.
        • Durie P.
        • Zini A.
        • Martin S.
        • et al.
        Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia.
        JAMA. 1999; 281: 2217-2224